Cost-effectiveness of smoking cessation treatment initiated during psychiatric hospitalization: Analysis from a randomized, controlled trial

Journal of Clinical Psychiatry

Volumn 76, Issue 10, 2015, Pages e1285-e1291

  Barnett, Paul G ^a,b,d   Wong, Wynnie ^a   Jeffers, Abra ^e   Hall, Sharon M ^a   Prochaska, Judith J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

^e Stanford University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; VARENICLINE;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; COMPUTER AIDED ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCREMENTAL COST EFFECTIVENESS RATIO; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; MORTALITY; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF HELP; SENSITIVITY ANALYSIS; SMOKING CESSATION; SMOKING CESSATION PROGRAM; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; MENTAL DISEASE; PROBABILITY; PROCEDURES; PSYCHOLOGY; SMOKING; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADULT; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HOSPITALIZATION; HUMANS; INPATIENTS; MALE; MARKOV CHAINS; MENTAL DISORDERS; SMOKING; SMOKING CESSATION;

EID: 84945388714     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14m09016     Document Type: Article

References (57)

1. Drummond MF. Methods for the economic evaluation of health care programmes. Oxford [u.a.]: Oxford Univ. Press; 2005.
2. Gold MR. Cost-effectiveness in health and medicine: Oxford University Press; 1996.
3. Prochaska JJ, Hall SE, Delucchi K, Hall SM. Efficacy of initiating tobacco dependence treatment in inpatient psychiatry: a randomized controlled trial. Am J Public Health 2013 Aug 15.
4. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 Mar;21(2):271-292.
5. Levy DT, Graham AL, Mabry PL, Abrams DB, Orleans CT. Modeling the impact of smoking-cessation treatment policies on quit rates. Am J Prev Med 2010 Mar;38(3 Suppl):S364-372.
6. Hyland A, Li Q, Bauer JE, Giovino GA, Steger C, Cummings KM. Predictors of cessation in a cohort of current and former smokers followed over 13 years. Nicotine Tob Res 2004 Dec;6 Suppl 3:S363-369.
7. Burns D, Anderson C, Johnson M. Cessation and cessation measures among daily adult smokers: national and state specific data. Bethesda, MD: National Cancer Institute; 2000.
8. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004 Jan;99(1):29-38.
9. Centers for Disease Control and Prevention (CDC). Smoking cessation during previous year among adults-United States, 1990 and 1991. MMWR Morb Mortal Wkly Rep 1993 Jul 9;42(26):504-507.
10. Centers for Disease Control and Prevention (CDC). Quitting smoking among adults - United States, 2001-2010. MMWR Morb Mortal Wkly Rep 2011 Nov 11;60(44):1513-1519.
11. Hawkins J, Hollingworth W, Campbell R. Long-term smoking relapse: a study using the british household panel survey. Nicotine Tob Res 2010 Dec;12(12):1228-1235.
12. Gilpin EA, Pierce JP, Farkas AJ. Duration of smoking abstinence and success in quitting. J Natl Cancer Inst 1997 Apr 16;89(8):572-576.
13. Wetter DW, Cofta-Gunn L, Fouladi RT, Cinciripini PM, Sui D, Gritz ER. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med 2004 Dec;39(6):1156-1163.
14. Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine Tob Res 2002 Feb;4(1):95-100.
15. Woloshin S, Schwartz LM, Welch HG. The risk of death by age, sex, and smoking status in the United States: putting health risks in context. J Natl Cancer Inst 2008 Jun 18;100(12):845-853.
16. Woloshin S, Schwartz LM, Welch HG. Risk charts: putting cancer in context. J Natl Cancer Inst 2002 Jun 5;94(11):799-804.
17. Prescott E, Osler M, Andersen PK, et al. Mortality in women and men in relation to smoking. Int J Epidemiol 1998 Feb;27(1):27-32.
18. Friedman GD, Tekawa I, Salder M, Sidney S. Smoking and mortality: the Kaiser Permanente experience. Changes in cigarette-related disease risks and their implications for prevention and control. Monogr Natl Cancer Inst 1997;97:472-499.
19. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking and smoking cessation in relation to mortality in women. JAMA 2008 May 7;299(17):2037-2047.
20. LaCroix AZ, Lang J, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl J Med 1991 Jun 6;324(23):1619-1625.
21. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. Ann Intern Med 1993 Nov 15;119(10):992-1000.
22. Streppel MT, Boshuizen HC, Ocke MC, Kok FJ, Kromhout D. Mortality and life expectancy in relation to long-term cigarette, cigar and pipe smoking: the Zutphen Study. Tob Control 2007 Apr;16(2):107-113.
23. Bjartveit K, Tverdal A. Health consequences of sustained smoking cessation. Tob Control 2009 Jun;18(3):197-205.
24. Taylor DH, Jr., Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. Am J Public Health 2002 Jun;92(6):990-996.
25. van Baal PH, Hoogenveen RT, de Wit GA, Boshuizen HC. Estimating health-adjusted life expectancy conditional on risk factors: results for smoking and obesity. Popul Health Metr 2006;4:14.
26. Sloan FA. The price of smoking: MIT Press; 2004.
27. Kelly DL, McMahon RP, Wehring HJ, et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull 2009 Jul;37(4):832-838.
28. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000 Sep;177:212-217.
29. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. The British Journal of Psychiatry 2010 February 1, 2010;196(2):116-121.
30. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007 Oct;64(10):1123-1131.
31. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997 Dec;171:502-508.
32. Harris EC, Barraclough B. Excess mortality of mental disorder. The British Journal of Psychiatry 1998 July 1, 1998;173(1):11-53.
33. McClave AK, McKnight-Eily LR, Davis SP, Dube SR. Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 National Health Interview Survey. Am J Public Health 2010 Dec;100(12):2464-2472.
34. Kinder LS, Bradley KA, Katon WJ, Ludman E, McDonell MB, Bryson CL. Depression, posttraumatic stress disorder, and mortality. Psychosom Med 2008 Jan;70(1):20-26.
35. Maheswaran H, Petrou S, Rees K, Stranges S. Estimating EQ-5D utility values for major health behavioural risk factors in England. J Epidemiol Community Health 2013 Feb;67(2):172-180.
36. Sullivan PW, Ghushchyan VH, Bayliss EA. The impact of co-morbidity burden on preference-based health-related quality of life in the United States. Pharmacoeconomics 2012 May;30(5):431-442.
37. Vogl M, Wenig CM, Leidl R, Pokhrel S. Smoking and health-related quality of life in English general population: implications for economic evaluations. BMC Public Health 2012;12:203.
38. Barton GR, Sach TH, Doherty M, Avery AJ, Jenkinson C, Muir KR. An assessment of the discriminative ability of the EQ-5Dindex, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions. Eur J Health Econ 2008 Aug;9(3):237-249.
39. Jia H, Lubetkin EI. Trends in quality-adjusted life-years lost contributed by smoking and obesity. Am J Prev Med 2010 Feb;38(2):138-144.
40. Ronckers ET, Groot W, Ament AJ. Systematic review of economic evaluations of smoking cessation: standardizing the cost-effectiveness. Med Decis Making 2005 Jul- Aug;25(4):437-448.
41. Woolacott NF, Jones L, Forbes CA, et al. The clinical effectiveness and costeffectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess 2002;6(16):1-245.
42. Fishman PA, Khan ZM, Thompson EE, Curry SJ. Health care costs among smokers, former smokers, and never smokers in an HMO. Health Serv Res 2003 Apr;38(2):733-749.
43. Fishman PA, Thompson EE, Merikle E, Curry SJ. Changes in health care costs before and after smoking cessation. Nicotine Tob Res 2006 Jun;8(3):393-401.
44. Hockenberry JM, Curry SJ, Fishman PA, et al. Healthcare costs around the time of smoking cessation. Am J Prev Med 2012 Jun;42(6):596-601.
45. Musich S, Faruzzi SD, Lu C, McDonald T, Hirschland D, Edington DW. Pattern of medical charges after quitting smoking among those with and without arthritis, allergies, or back pain. Am J Health Promot 2003 Nov-Dec;18(2):133-142.
46. O'Donnell MP, Roizen MF. The SmokingPaST Framework: illustrating the impact of quit attempts, quit methods, and new smokers on smoking prevalence, years of life saved, medical costs saved, programming costs, cost effectiveness, and return on investment. Am J Health Promot 2011 Sep-Oct;26(1):e11-23.
47. Solberg LI, Maciosek MV, Edwards NM, Khanchandani HS, Goodman MJ. Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectiveness. Am J Prev Med 2006 Jul;31(1):62-71.
48. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. [cited; Available from: http://meps.ahrq.gov/mepsweb/
49. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 updated March 2011 ed: The Cochrane Collaboration; 2011.
50. Bronnum-Hansen H, Juel K. Abstention from smoking extends life and compresses morbidity: a population based study of health expectancy among smokers and never smokers in Denmark. Tob Control 2001 Sep;10(3):273-278.
51. Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008;26(6):497-511.
52. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. Jama 1996 Apr 24;275(16):1247-1251.
53. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. Jama 1997 Dec 3;278(21):1759-1766.
54. Chirikos TN, Herzog TA, Meade CD, Webb MS, Brandon TH. Cost-effectiveness analysis of a complementary health intervention: the case of smoking relapse prevention. Int J Technol Assess Health Care 2004 Fall;20(4):475-480.
55. Javitz HS, Swan GE, Zbikowski SM, et al. Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. Am J Manag Care 2004 Mar;10(3):217-226.
56. Godfrey C, Parrott S, Coleman T, Pound E. The cost-effectiveness of the English smoking treatment services: evidence from practice. Addiction 2005 Apr;100 Suppl 2:70-83.
57. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994;3(5):309-319.